The overall innovation ability of pharmaceutical enterprises is limited. Innovation is the lifeline of pharmaceutical industry. The innovation power of the pharmaceutical industry mainly comes from two aspects: first, human health is constantly threatened by various new diseases, and the pharmaceutical industry must constantly expand its own development fields; Second, the variation of bacteria and viruses reduces the curative effect of traditional drugs, and urges human beings to speed up the pace of drug upgrading.
The pharmaceutical industry is also an industry with high investment, high return and high risk. Because the pharmaceutical industry has been facing great pressure of continuous innovation, pharmaceutical companies must increase their research and development efforts. The pharmaceutical industry in developed countries spends 10%~20% of its sales on the research and development of new drugs, and it costs more than 200-300 million dollars to successfully develop a new chemically synthesized drug.
In 2003, the total output value of China pharmaceutical industry was 654.38+02 billion RMB, which was not as good as the annual output value of international pharmaceutical giant Merck. However, in recent years, the R&D investment of the whole pharmaceutical industry in China only hovered around 654.38+0% of the total sales.
Pharmaceutical products are mainly generic drugs with low technical content. Generic drugs refer to relatively common drugs, which have the characteristics of universal clinical application, definite curative effect, large dosage and low price, and are mostly national essential drugs. Most manufacturers of generic drugs are small and medium-sized enterprises, lacking financial strength, research and development strength, marketing network and other foundations. Therefore, compared with new drugs and special drugs, its technical content is low, resulting in low added value.
Generally speaking, China's pharmaceutical level is still significantly lower than the international advanced level, and the ratio of added value of preparations to raw materials is 3: 1, which is only one tenth of that of the United States. In the increasingly fierce market competition, the operating efficiency of generic drug manufacturers is generally poor.
Drugs lacking independent intellectual property rights. China's preparation production is backward, mainly imitating foreign new drugs and lacking independent intellectual property rights. Due to the lack of innovation ability of China's pharmaceutical industry, domestic drugs circulating in China's market are basically not original new drugs, and the production of generic drugs has always been the fulcrum of China's pharmaceutical industry development.
In fact, apart from Chinese medicine, there are almost no drugs with independent intellectual property rights in China.
The above content source: Baidu Encyclopedia-Pharmaceutical Manufacturing Industry